WebOct 19, 2024 · As a first-line therapy for the treatment of secondary Raynaud phenomenon (RP), phosphodiesterase type 5 (PDE5) inhibitors are more effective than a placebo at reducing the frequency, severity, and the duration of RP attacks. ... Two guidelines recommend calcium channel blockers as first-line therapy based on high … WebAug 5, 2024 · Indications. In the 1970s, calcium channel antagonists, also known as calcium channel blockers, were widely used for many indications. This cardiovascular drug class is one of the leading causes of drug-related fatalities. They often classify into two major categories, either non-dihydropyridines or dihydropyridines.

Raynaud Phenomenon Treatment & Management - Medscape

WebAug 1, 2014 · CCBs are the most widely used medications for Raynaud phenomenon. Other agents, such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, … WebA meta-analysis (11 studies, n=361) of secondary Raynaud’s phenomenon (related to systemic sclerosis) reported that treatment with calcium channel blockers led to a … coach of maple leafs

Treatment of Raynaud

WebRaynaud’s phenomenon is a common condition in people with scleroderma. Blood flow to your fingers is greatly reduced because the blood vessels become narrowed or constricted. Sometimes, your toes, feet, ankles or other body parts are affected too. ... Calcium channel blockers: Nifedipine or amlodipine. Possible side effects: ... WebJan 15, 2016 · Side effects from taking calcium channel blockers are usually fairly mild, but may include: Weight gain. Swelling in the lower legs, feet, or ankles. Feeling dizzy. … WebFeb 22, 1985 · The pathophysiology of Raynaud's phenomenon is varied, but digital ischemia is an essential element. Because calcium channel blockers cause arteriolar vasodilation and an increase in peripheral blood flow, they have been used to treat patients with Raynaud's phenomenon in several prospective, randomized, double-blind, placebo … caliburn chs